Microbix granted patent for influenza vaccine yield enhancement technology

May 28, 2008 (Datamonitor via COMTEX) -- MBXBF | Quote | Chart | News | PowerRating -- Microbix Biosystems has received a patent from the Intellectual Property Office of the People's Republic of China for its Virusmax technology which enables egg-based vaccine manufacturers to increase the amount of influenza vaccine they produce each year.

Virusmax has enormous implications for protecting more of the world's population during a pandemic. The entire annual global flu vaccine production capacity is currently only about 350 million doses. Virusmax can enable manufacturers to at least double the amount of influenza vaccine they produce, reducing dependence on imported supplies.

William Gastle, CEO of Microbix, said: "China is one of the largest countries in the world that does not have domestic manufacturing capacity to supply its population with seasonal and pandemic influenza vaccine and would benefit from having access to this technology."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index